FATE Fate Therapeutics Corp: Bozor kapitallashuvining balans qiymatiga nisbati

Fate Therapeutics Corp (FATE) - korporativ logo

Fate Therapeutics, Inc. (FATE) rivojlanishi biomateriallarning qat'iy termik nazorat ostidagi xavfsiz havo yo'llari orqali samarali yetkazib berilishiga va o'simtalarga qarshi iPSC asosidagi dori vositalarining muvaffaqiyatli sinovlariga bog'liq. Ushbu narxlar grafigi 1.59 ko'rsatkichini aks ettirdi. Kotirovkalar sog'liqni saqlash gigantlari bilan strategik sherikliklar ma'lumotlari bilan to'ldirilgan. Chuqur ilmiy tajribaga ega bo'lgan kompaniyaning rahbariyati og'ir kasalliklarni davolash uchun universal hujayra mahsulotlarini yaratishga ixtisoslashgan.

Fate Therapeutics, Inc. (FATE) - Bozor kapitallashuvining balans qiymatiga nisbati 04.07.2022dan 28.10.2026gacha

FATE (Fate Therapeutics Inc): tahliliy kesimlar va indikatorlar boʻyicha maʼlumotlar

- narx va narxlar bo'yicha konsensus prognoz:
Aksiya narxi Fate Therapeutics, Inc.|FATE - Oʻrtacha prognoz narxi
- bozor kapitallashuvi bo'yicha ma'lumotlar:
Bozor kapitallashuvi Fate Therapeutics Corp|FATE - Kompaniyani butunlay sotib olishdagi haqiqiy narx
- balans kapitallashuvi bo'yicha ma'lumotlar:
Bitta aksiya hisobiga balans qiymati Fate Therapeutics|FATE - Balans kapitallashuvi|Bozor qiymatining balans qiymatiga nisbati fatetherapeutics.com|FATE - Biznesning umumiy aktivlari
- qarz va likvidlik bo'yicha ma'lumotlar:
Umumiy qarzning kapitalga nisbati Fate Therapeutics, Inc.|FATE - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati Fate Therapeutics Corp|FATE - Kompaniyaning umumiy yig'indi qarzi|Qarzning balans kapitallashuviga nisbati Fate Therapeutics Corp|FATE - Kompaniyaning uzoq muddatli kredit va qarzlari|Kompaniyaning qisqa muddatli majburiyatlari Fate Therapeutics
Fundamental baholash:FATE (Fate Therapeutics, Inc.)
Fate Therapeutics Inc tayyor mahsulotlari

Ushbu koeffitsient biznesning bozor qiymatini uning sof aktivlari bilan solishtiradi, bu esa aktivning haddan tashqari qimmat baholangani yoki fundamental xavfsiz boshpana zaxirasiga ega ekanligini real vaqt rejimida baholash imkonini beradi. iPSC platformasini ishlab chiqish va NK-hujayralar ishlab chiqarishni kengaytirish kontekstida Fate Therapeutics, Inc. (FATE) ning nisbiy kapitalizatsiyasini tahlil qilish, leukemia terapiyasidagi yutuqlarga bo'lgan bozor kutuvlari emitentning haqiqiy balans hisoboti qiymati bilan qanchalik darajada asoslanganini baholashga yordam beradi.

Asosiy raqobatchilar

Bozor kapitallashuvining balans qiymatiga nisbati ONC|halozyme.com (HALO) - Bozor qiymatining balans qiymatiga koeffitsiyenti|Bozor kapitallashuvining balans qiymatiga nisbati RVMD|Kapitallashuvning sof aktivlarga nisbati Ascentage Pharma Group International|Bozor kapitallashuvining balans qiymatiga nisbati CGON|Bozor kapitallashuvining balans qiymatiga nisbati URGN (UroGen Pharma Corp)|BCAX - Bozor qiymatining balans qiymatiga nisbati|Kapitallashuvning balans qiymatiga nisbati personalis.com PSNL|ERAS: Bozor kapitallashuvining balans qiymatiga nisbati|DCTH - Kapitallashuvning sof aktivlarga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati YMAB|AURA (Aura Corp) - Bozor qiymatining balans qiymatiga koeffitsiyenti|CADL - Bozor qiymatining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor qiymati accuray.com (ARAY)|SELLAS Life Sciences (SLS) - Kapitallashuvning sof aktivlarga nisbati|Balans qiymatiga nisbatan bozor qiymati Actuate Therapeutics Inc. (ACTU)|Citius Oncology, Inc - Bozor kapitallashuvining balans qiymatiga nisbati|HURA - Kapitallashuvning sof aktivlarga nisbati|Protara Therapeutics - Kapitallashuvning sof aktivlarga nisbati|WHWK: Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga nisbati tscan.com TCRX|Champions Oncology, Inc. (CSBR) - Balans qiymatiga nisbatan bozor qiymati|Bozor kapitallashuvining balans qiymatiga nisbati XBIT (XBiotech Inc)|Bozor qiymatining balans qiymatiga koeffitsiyenti CEL-SCI Corp|OSTX - Bozor kapitallashuvining balans qiymatiga nisbati|Sof aktivlarga nisbatan bozor kapitallashuvi Radiopharm Theranostics Ltd (RADX)|Bozor kapitallashuvining balans qiymatiga nisbati ARTV (Artiva Biotherapeutics)|ANL - Bozor kapitallashuvining balans qiymatiga nisbati|Kapitallashuvning sof aktivlarga nisbati Veru Pharma VERU|TPST - Bozor kapitallashuvining balans qiymatiga multiplikatori|Bozor kapitallashuvining balans qiymatiga nisbati XLO|Bozor qiymatining balans qiymatiga koeffitsiyenti Renovaro|MURA - Kapitallashuvning sof aktivlarga nisbati|Balans qiymatiga nisbatan bozor qiymati Kairos Pharma Inc (KAPA)|Kapitallashuvning sof aktivlarga nisbati OnKure Therapeutics Inc|Bozor kapitallashuvining balans qiymatiga multiplikatori w2.cytomed.sg (GDTC)|Bozor kapitallashuvining balans qiymatiga nisbati Curis|Balans qiymatiga nisbatan bozor qiymati Apollomics Inc. APLM|THAR (Tharimmune) - Bozor kapitallashuvining balans qiymatiga nisbati|ADVB: Bozor qiymatining balans qiymatiga koeffitsiyenti|Bozor qiymatining balans qiymatiga nisbati Genprex, Inc GNPX|Calidi Biotherapeutics, Inc. (CLDI) - Balans qiymatiga nisbatan bozor qiymati|SBFM (Sunshine Biopharma) - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati XBIO|SLRX - Bozor qiymatining balans qiymatiga nisbati|Sof aktivlarga nisbatan bozor kapitallashuvi Purple Biotech Ltd (PPBT)|AONC: Bozor kapitallashuvining balans qiymatiga nisbati|BGNE - Bozor qiymatining balans qiymatiga koeffitsiyenti|Checkpoint Therapeutics - Kapitallashuvning sof aktivlarga nisbati|Elevation Oncology Inc. (ELEV) - Bozor kapitallashuvining balans qiymatiga nisbati|ICAD - Kapitallashuvning sof aktivlarga nisbati|Ikena Oncology (IKNA) - Bozor kapitallashuvining balans qiymatiga multiplikatori|NTBL: Bozor kapitallashuvining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor kapitallashuvi Viracta|Bozor kapitallashuvining balans qiymatiga nisbati MOR (MorphoSys AG)|Kapitallashuvning sof aktivlarga nisbati NAYA (nayabiosciences.com)|Bozor qiymatining balans qiymatiga nisbati AAPGV